Clinical Trials Logo

Filter by:
NCT ID: NCT01255787 Completed - Clinical trials for Depressive Disorder, Major

Efficacy and Safety Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive Disorder

Start date: November 2010
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to assess the efficacy and safety of multiple doses of vortioxetine, once daily (QD), in participants with major depressive disorder.

NCT ID: NCT01254019 Completed - Clinical trials for Muscular Dystrophies

A Clinical Study to Assess the Efficacy and Safety of GSK2402968 in Subjects With Duchenne Muscular Dystrophy

DMD114044
Start date: December 2, 2010
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether GSK2402968 is effective in the treatment of ambulant boys with Duchenne muscular dystrophy resulting from a mutation thought to be corrected by exon 51 skipping.

NCT ID: NCT01253525 Completed - Adenocarcinoma Clinical Trials

Study of Weekly Paclitaxel With Ramucirumab in Participants With Advanced Gastric Adenocarcinomas

Start date: November 2010
Phase: Phase 1
Study type: Interventional

Investigate the safety and tolerability of ramucirumab (IMC-1121B) drug product (DP) in combination with paclitaxel.

NCT ID: NCT01253434 Completed - Clinical trials for Japanese Healthy Male Adult Volunteers

E2022 Patch Formulation Single Dose Phase I Study

Start date: November 2010
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the pharmacokinetics of a single dose of E2022 in healthy Japanese male volunteers.

NCT ID: NCT01253291 Completed - Clinical trials for Rheumatoid Arthritis

A Study of Japanese Rheumatoid Arthritis Participants

Start date: May 2010
Phase: Phase 1
Study type: Interventional

The objective of this study is to evaluate the safety and tolerability of 48 weeks subcutaneous (SC) dosing with LY2127399 for participants who have participated in a prior LY2127399 clinical study. At the end of the 48-week treatment period, participants will participate in a 24-week follow-up period. Additional follow up after Week 72 may continue to assess B-cell recovery.

NCT ID: NCT01253265 Completed - Clinical trials for Rheumatoid Arthritis

A Study in Rheumatoid Arthritis

Start date: May 2010
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of multiple doses of LY2439821 in Japanese patients with rheumatoid arthritis.

NCT ID: NCT01253226 Completed - Clinical trials for Rheumatoid Arthritis

A Study for Japanese Participants With Rheumatoid Arthritis (RA)

Start date: September 2009
Phase: Phase 1
Study type: Interventional

This study will evaluate the safety and tolerability of multiple doses of LY2127399 (tabalumab) in Japanese participants with RA. The study consists of a 20-week treatment period. All participants will be followed for up to 12 weeks after the last study drug administration.

NCT ID: NCT01252147 Completed - Healthy Volunteers Clinical Trials

Inter-rater and Intra-rater Reliability Study of the Global Eyelash Assessment Scale for Assessment of Overall Eyelash Prominence

Start date: December 2010
Phase: N/A
Study type: Observational

This study will evaluate the inter-rater and intra-rater reliability of the Global Eyelash Assessment (GEA) scale with photonumeric guide in Japanese subjects.

NCT ID: NCT01251796 Completed - Clinical trials for Advanced/Recurrent Non-small-cell Lung Cancer

A Study of ARQ 197 in Combination With Erlotinib

Start date: December 2010
Phase: Phase 1
Study type: Interventional

This is a phase I study to determine the safety, tolerability and recommended phase II dose of ARQ 197 given in combination with erlotinib as primary endpoints in CYP2C19 poor metabolizer patients with advanced/recurrent non-small-cell lung cancer. The pharmacokinetic profile and antitumor activity of ARQ 197 administered alone or in combination with erlotinib will also be determined as secondary endpoints.

NCT ID: NCT01251718 Completed - Alzheimer's Disease Clinical Trials

Post-marketing Surveillance of Donepezil Hydrochloride -Investigation of the Clinical Safety and Effectiveness in Patients With Alzheimer's Disease

Start date: December 1, 2010
Phase:
Study type: Observational

To investigate the clinical safety and effectiveness of donepezil hydrochloride administration in patients with mild or moderate Alzheimer's Disease